Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Test preparation:Methylcholine chloroacetate for inhalation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Asthma
1 trial -
Test preparation:Methylcholine chloroacetate for inhalation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy People
1 trial -
Thymosin Alpha 1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatitis, Acute Necrotizing
1 trial -
Ticagrelor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
1 trial -
Ticagrelor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
Tirofiban hydrochloride sodium chloride injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Branch Atheromatous Disease
1 trial -
Tofacitinib and Acitretin Capsules.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Cutaneous Amyloidosis
1 trial -
Treatment group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Trimetazidine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
1 trial -
Triple combination therapy group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Type 2 Diabetes Mellitus
1 trial -
Triptergium Wilfordii
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Psoriasis Vulgaris
1 trial -
Ursodeoxycholic acid combined with total glucosides of paeony
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis
1 trial -
Vardenafil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Erectile Dysfunction
1 trial -
Wangbi granules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rheumatoid Arthritis
1 trial -
Warfarin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anticoagulation
1 trial -
Wen Xin granule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
1 trial -
Xiang Sha Liu Jun Zi Decoction dry powder
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma
1 trial -
Xingnaojing injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
Xuebijing Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sepsis
2 trials -
Xuesaitong Soft Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
2 trials -
Xueshuanxinmaining tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Heart Disease
1 trial -
Zhenyuan capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stable Coronary Heart Disease
1 trial -
Zushima plaster with high dose
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Osteoarthritis
1 trial -
albumin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sepsis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources